2020
Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network
Hundt MA, Deng Y, Ciarleglio MM, Nathanson MH, Lim JK. Abnormal Liver Tests in COVID‐19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network. Hepatology 2020, 72: 1169-1176. PMID: 32725890, PMCID: PMC9258788, DOI: 10.1002/hep.31487.Peer-Reviewed Original ResearchConceptsAbnormal liver testsLiver testsCohort studyClinical outcomesCOVID-19Yale New Haven Health SystemCoronavirus-19 disease (COVID-19) pandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virusRetrospective observational cohort studyAcute respiratory distress syndromeRetrospective cohort studyLiver test abnormalitiesObservational cohort studySevere COVID-19Liver transaminase elevationsRespiratory distress syndromeBody mass indexPoor clinical outcomeCoronavirus 2 virusCOVID-19 treatmentNonpulmonary manifestationsPeak hospitalizationsICU admissionMultiorgan failureTransaminase elevation
2018
Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B
Nguyen MH, Ozbay AB, Liou I, Meyer N, Gordon SC, Dusheiko G, Lim JK. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. Journal Of Hepatology 2018, 70: 24-32. PMID: 30287341, DOI: 10.1016/j.jhep.2018.09.021.Peer-Reviewed Original ResearchConceptsAdvanced liver diseaseCompensated liver diseaseLiver diseaseDisease severityCause inpatientLiver transplantHepatitis BHealthcare utilizationHepatocellular carcinomaHigh emergency department (ED) utilizationHighest mean annual costCause inpatient admissionsChronic hepatitis BDisease statesHealthcare resource utilizationLiver disease groupEmergency department utilizationEmergency room visitsHepatocellular carcinoma groupProgressive disease statesPharmaceutical utilizationMean annual costLiver disease statesProgressive diseaseHepatitis B.
2015
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study
Ahn J, Lee HM, Lim JK, Pan CQ, Nguyen MH, Kim W, Mannalithara A, Trinh H, Chu D, Tran T, Min A, Do S, Te H, Reddy KR, Lok AS. Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study. Alimentary Pharmacology & Therapeutics 2015, 43: 134-144. PMID: 26510638, PMCID: PMC4926997, DOI: 10.1111/apt.13440.Peer-Reviewed Original ResearchConceptsALT normalisationAdverse eventsHBV DNAHBeAg(-) patientsHBV patientsTreatment-naïve chronic hepatitis B patientsChronic hepatitis B patientsFive-year cumulative probabilityHBsAg loss/seroconversionLog 10 IU/Hepatitis B virus infectionEffectiveness of entecavirMedian HBV DNAUndetectable HBV DNAHepatitis B patientsB virus infectionAbnormal ALTEntecavir treatmentETV treatmentHBeAg lossHBsAg lossHepatic decompensationB patientsCohort studyMedian durationDrug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, Sapir D, Wright J, Eggers C, Drozd K, Ciarleglio M, Deng Y, Lim JK. Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade. PLOS ONE 2015, 10: e0135645. PMID: 26312999, PMCID: PMC4552165, DOI: 10.1371/journal.pone.0135645.Peer-Reviewed Original ResearchConceptsSofosbuvir/ledipasvirViral loadMedicaid coverageChild-Pugh class B diseaseInitial approvalEnd-stage liver disease (MELD) scoreStage liver disease scoreChronic HCV infectionClass B diseaseDrug authorizationHCV care cascadeSOF/LEDAdvanced liver diseaseBaseline viral loadHepatitis C infectionLiver Disease scoreRetrospective chart reviewHigh viral loadSignificant predictorsHigher likelihoodMedicare/MedicaidSOF/C infectionCare cascadeHCV infectionEmerging trends in hepatocellular carcinoma incidence and mortality
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015, 61: 191-199. PMID: 25142309, PMCID: PMC4823645, DOI: 10.1002/hep.27388.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, HepatocellularFemaleHumansIncidenceLiver NeoplasmsMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesSEER ProgramUnited StatesConceptsIB mortalityHCC incidenceHepatocellular carcinomaIncidence of HCCMultivariable Cox regression analysisOverall median survivalCox regression analysisEnd Results (SEER) dataSignificant survival improvementAge-adjusted incidenceU.S. populationHepatocellular carcinoma incidenceJoinpoint Regression ProgramIncidence-based mortalityRegression analysisSignificant increaseCurative modalityLiver transplantCurative stageMedian survivalSurvival improvementCarcinoma incidenceTumor sizeVascular invasionPrimary tumor